Stay Ahead of Wall Street. Find out what is happening to Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) stock today? Its price is jumping 0.12 points, trading at $4.41 levels, and is up 2.91% from its previous close of $4.29. The shares seem to have an active trading volume day with a reported 125673 contracts so far this session. ADMS shares had a relatively better volume day versus average trading capacity of 411.62 thousand shares, but with a 26.85 million float and a -15.05% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for ADMS stock indicates that the average analyst price target is $28.78 per share. This means the stock has a potential increase of 552.61% from where the ADMS share price has been trading recently which is between $4.255 and $4.67. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $8.
The shorts are running away from Adamas Pharmaceuticals, Inc. (ADMS) stock. The latest set of short interest data was released on 31 May 2019, and the numbers show a drop in short interest in ADMS shares. While short interest still represents only 21.42% of ADMS’s float, the number of shares shorted have fallen by -436338. The number of shares shorted fell to 5314961 shares, down from 5751299 shares during the preceding fortnight. With average daily trading volumes at 602504 shares, days to cover decreased to about 13.31492 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm” and dated June 11, 2019.
During the recent trading session for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), the company witnessed their stock drop by $-0.36 over a week and tumble down $-1.05 from the price 20 days ago. When compared to their established 52-week high of $29.49, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 08/03/18. The recent low of $4.2 stood for a -85.03% since 06/12/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.5 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Adamas Pharmaceuticals, Inc., the two-week RSI stands at 31.31. This figure suggests that ADMS stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current ADMS readings is similarly very revealing as it has a stochastic reading of 13.63% at this stage. This figure means that ADMS share price today is being overbought.
Technical chart claims that Adamas Pharmaceuticals, Inc. (ADMS) would settle between $4.55/share to $4.82/share level. However, if the stock price goes below the $4.14 mark, then the market for Adamas Pharmaceuticals, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $3.99 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.21. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Mizuho lowered their recommendation on shares of ADMS from Neutral to Underperform in their opinion released on March 05. Mizuho analysts have lowered their rating of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) stock from Buy to Neutral in a separate flash note issued to investors on November 05. Analysts at BofA/Merrill lowered the stock to a Neutral call from its previous Buy recommendation, in a research note that dated back to October 05.
ADMS equity has an average rating of 2.18, with the figure leaning towards a bullish end. 11 analysts who tracked the company were contacted by Reuters. Amongst them, 3 rated the stock as a hold while the remaining 8 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while others rated it as a sell. 7 analysts rated Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) as a buy or a strong buy while 1 advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, ADMS stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 2939.55 while for the average stock in the same group, the multiple is 49.5.
Adamas Pharmaceuticals, Inc. (ADMS)’s current-quarter revenues are projected to climb by nearly 68.51% to hit $12.76 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over 61.83% from $34.05 million to a noteworthy $55.1 million. At the other end of the current quarter income statement, Adamas Pharmaceuticals, Inc. is expected to see its adjusted earnings surge by roughly 23.02% to hit $-0.97 per share. For the fiscal year, ADMS’s earnings are projected to climb by roughly 22.59% to hit $-3.77 per share.